| Recruiting | Pilot Study of Reduced Venetoclax Exposure NCT07163793 | Northwell Health | Phase 2 |
| Recruiting | Ziftomenib Maintenance Post Allo-HCT NCT06440135 | Massachusetts General Hospital | Phase 1 |
| Recruiting | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transpla NCT06462365 | Tr1X, Inc. | Phase 1 |
| Active Not Recruiting | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion NCT05236764 | Baylor College of Medicine | N/A |
| Recruiting | Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to All NCT05917405 | Nantes University Hospital | Phase 2 |
| Recruiting | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880 | Medical College of Wisconsin | N/A |
| Active Not Recruiting | Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events NCT05224661 | Center for International Blood and Marrow Transplant Research | — |
| Completed | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat NCT04712942 | University of Leipzig | Phase 2 |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Unknown | Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML NCT04490707 | Ge Zheng | Phase 3 |
| Unknown | Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Ac NCT04747002 | Osaka University | Phase 2 |
| Active Not Recruiting | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leu NCT04232241 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Unknown | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cel NCT03887156 | Assistance Publique - Hôpitaux de Paris | Phase 2 / Phase 3 |
| Active Not Recruiting | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission NCT04062266 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Red NCT03852407 | University of Liege | Phase 2 |
| Withdrawn | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344 | City of Hope Medical Center | Phase 2 |
| Unknown | Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid NCT03697707 | Mendus | Phase 2 |
| Active Not Recruiting | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Tran NCT03560752 | City of Hope Medical Center | Phase 1 |
| Suspended | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treatin NCT03494569 | City of Hope Medical Center | Phase 1 |
| Completed | Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid Leukemia NCT04617145 | Cairo University | N/A |
| Active Not Recruiting | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML NCT03286530 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV a NCT02506933 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced I NCT02528877 | City of Hope Medical Center | Phase 1 |
| Completed | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelo NCT02446964 | City of Hope Medical Center | Phase 1 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in R NCT02083250 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leuke NCT01894477 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating NCT01690520 | Nohla Therapeutics, Inc. | Phase 2 |
| Completed | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malig NCT01413568 | Polyphor Ltd. | Phase 1 / Phase 2 |
| Terminated | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer W NCT00796068 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, NCT00453388 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478 | Fred Hutchinson Cancer Center | Phase 3 |